← All trials
NCT05942820
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Jul 12, 2023
- Last posted
- Sep 5, 2023
- Enrollment
- 56
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bugworks Research Inc.Lead sponsor
- Avance Clinical Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.